Highlights
- Market Cap
- $5.30B
- Enterprise Value
- $5.14B
- EPS (TTM)
- -$1.90
- EBITDA (TTM)
- -$61.02M
- Year Range
- $49.00 - $200.00
- Target Price
- $191.40
- ROA (TTM)
- -22.09%
- ROE (TTM)
- -22.76%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Belite Bio Inc ADR, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Belite Bio Inc ADR (BLTE) has returned -0.33% so far this year and 140.77% over the past 12 months.
Belite Bio Inc ADR
- 1D
- 6.88%
- 1M
- -16.22%
- YTD
- -0.33%
- 6M
- 115.46%
- 1Y
- 140.77%
- 3Y*
- 74.71%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Apr 29, 2022, BLTE's average daily return is +0.38%, while the average monthly return is +8.22%. At this rate, your investment would double in approximately 0.7 years.
Historically, 53% of months were positive and 47% were negative. The best month was Jun 2022 with a return of +106.0%, while the worst month was May 2023 at -43.0%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.
On a daily basis, BLTE closed higher 52% of trading days. The best single day was May 3, 2022 with a return of +30.8%, while the worst single day was May 31, 2023 at -31.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.65% | 12.60% | -16.22% | -0.33% | |||||||||
| 2025 | -8.02% | -1.45% | 15.77% | -7.16% | 5.51% | -11.05% | 12.67% | -3.05% | 17.40% | 43.11% | 29.78% | 16.39% | 153.50% |
| 2024 | -5.07% | 6.49% | -17.04% | 5.81% | 20.57% | -6.68% | 8.36% | -1.66% | -3.70% | 42.09% | -5.03% | -0.25% | 37.92% |
| 2023 | -0.85% | 10.74% | -9.67% | -3.24% | -43.00% | -13.34% | 62.49% | 47.93% | -7.28% | 17.77% | 12.16% | 8.75% | 51.77% |
| 2022 | 42.77% | 105.96% | 7.90% | -4.43% | 4.48% | -13.35% | 12.73% | -8.01% | 184.66% |
Benchmark Metrics
Belite Bio Inc ADR has an annualized alpha of 152.77%, beta of 0.23, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since May 02, 2022.
- This stock captured 83.67% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -699.62%) — a profile typical of hedging or uncorrelated assets.
- Beta of 0.23 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 152.77%
- Beta
- 0.23
- R²
- 0.00
- Upside Capture
- 83.67%
- Downside Capture
- -699.62%
Return for Risk
Risk / Return Rank
BLTE ranks 94 for risk / return — in the top 94% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Belite Bio Inc ADR (BLTE) and compare them to a chosen benchmark (S&P 500 Index).
| BLTE | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.66 | 0.90 | +1.76 |
Sortino ratioReturn per unit of downside risk | 3.19 | 1.39 | +1.81 |
Omega ratioGain probability vs. loss probability | 1.40 | 1.21 | +0.19 |
Calmar ratioReturn relative to maximum drawdown | 6.43 | 1.40 | +5.04 |
Martin ratioReturn relative to average drawdown | 17.29 | 6.61 | +10.69 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore BLTE risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Belite Bio Inc ADR. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Belite Bio Inc ADR was 74.59%, occurring on Jun 23, 2023. Recovery took 120 trading sessions.
The current Belite Bio Inc ADR drawdown is 16.22%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -74.59% | Jul 6, 2022 | 244 | Jun 23, 2023 | 120 | Dec 13, 2023 | 364 |
| -36.6% | Nov 15, 2024 | 41 | Jan 16, 2025 | 188 | Oct 16, 2025 | 229 |
| -32.66% | Feb 15, 2024 | 43 | Apr 17, 2024 | 30 | May 30, 2024 | 73 |
| -23.75% | May 9, 2022 | 8 | May 18, 2022 | 15 | Jun 9, 2022 | 23 |
| -21.61% | Mar 2, 2026 | 19 | Mar 26, 2026 | — | — | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Belite Bio Inc ADR over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Belite Bio Inc ADR is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BLTE in comparison with other companies in the Biotechnology industry. Currently, BLTE has a P/B value of 19.3. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |